ARWR
Arrowhead Pharmaceuticals Inc
71.90$
+4.5%
vs. previous close
Closing price · As of: Sep 22, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 2,176.2% | 21,461.8% | 52,075.1% | 202.9% | 417.4% | – | – | – | 4.3% | 5.2% | 523.7% | 2.9% | |
| -2,076.2% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 94.8% | -423.7% | 100.0% | |
| 13,221.7% | 12,373.7% | 26,181.8% | 147.3% | 299.2% | 45.4% | 140.4% | 149.2% | 122.2% | 142.2% | 13,776.9% | 73.2% | |
| 13,954.0% | 9,088.5% | 14,902.1% | 55.7% | 118.4% | 15.7% | 59.4% | 58.6% | 51.2% | 37.8% | 2,726.6% | 14.7% | |
| 27,126.0% | 21,462.2% | 52,075.5% | 202.9% | 417.4% | 61.1% | 199.1% | 207.8% | 173.4% | 180.0% | 16,503.4% | 88.1% | |
| -30,443.6% | -25,124.1% | -51,627.1% | -117.8% | -346.5% | 36.3% | -105.9% | -107.8% | -73.4% | -85.2% | -16,927.1% | 11.9% | |
| 368,853.1% | 190,879.1% | 167,870.2% | 1,321.7% | 6,495.5% | 4,122.0% | 10,444.7% | 4.4% | 2.1% | 7.6% | 911.1% | 10.8% | |
| -33,554.3% | -24,067.7% | -51,613.1% | -109.5% | -337.3% | 40.4% | -96.1% | -101.9% | -71.0% | -85.8% | -17,247.5% | 6.2% | |
| 3.0% | 0.6% | 1.5% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 1.6% | 1.2% | -77.9% | 2.6% | |
| -33,503.0% | -24,068.3% | -51,614.6% | -109.5% | -337.3% | 40.3% | -96.1% | -101.9% | -72.6% | -85.3% | -16,882.4% | -0.2% | |
| -28,433.3% | -24,512.5% | -48,272.9% | -102.9% | -317.4% | 38.9% | -99.1% | -95.9% | -69.1% | -73.0% | -15,812.8% | 19.9% |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.